ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tafenoquine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2018-06-04

Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.

Goyal N, Mohamed K, Rolfe K, Sahota S, Ernest T, Duparc S, Taylor M, Casillas L, Koh GCKW.

AAPS J · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1208/s12248-018-0234-5

Bibliografisk träff 2018-04-20

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.

Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ.

PLoS Negl Trop Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pntd.0006440

Bibliografisk träff 2017-11-09

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C.

PLoS One · research-article; randomized controlled trial; journal article · DOI 10.1371/journal.pone.0187376

Bibliografisk träff 2017-07-27

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (<i>G6PD Mahidol</i> Variant) versus G6PD-Normal Volunteers.

Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Möhrle JJ, Rousell V, Mohamed K, Qureshi A, Narayan S, Yubon N, Miller A, Nosten FH, Luzzatto L, Duparc S, Kleim JP, Green JA.

Am J Trop Med Hyg · research-article; journal article · DOI 10.4269/ajtmh.16-0779

Bibliografisk träff 2017-05-19

The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).

Dow G, Smith B.

Malar J · research support, non-u.s. gov't; review-article; review; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1186/s12936-017-1862-4

Bibliografisk träff 2017-05-08

Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis.

Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S.

Travel Med Infect Dis · journal article · DOI 10.1016/j.tmaid.2017.05.008

Bibliografisk träff 2017-05-08

Tafenoquine is not neurotoxic following supertherapeutic dosing in rats.

Dow GS, Brown T, Reid M, Smith B, Toovey S.

Travel Med Infect Dis · journal article · DOI 10.1016/j.tmaid.2017.05.006

Bibliografisk träff 2017-03-11

Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum.

Kemirembe K, Cabrera M, Cui L.

Int J Parasitol Drugs Drug Resist · research-article; journal article · DOI 10.1016/j.ijpddr.2017.03.002

Bibliografisk träff 2017-01-26

Effects of Antimalarial Tafenoquine on Blood Platelet Activity and Survival.

Cao H, Bissinger R, Umbach AT, Al Mamun Bhuyan A, Lang F, Gawaz M.

Cell Physiol Biochem · journal article · DOI 10.1159/000456319

Bibliografisk träff 2016-12-13

Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum.

Tasai S, Saiwichai T, Kaewthamasorn M, Tiawsirisup S, Buddhirakkul P, Chaichalotornkul S, Pattaradilokrat S.

Vet Parasitol · journal article · DOI 10.1016/j.vetpar.2016.12.008

Bibliografisk träff 2016-11-21

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.

Green JA, Mohamed K, Goyal N, Bouhired S, Hussaini A, Jones SW, Koh GC, Kostov I, Taylor M, Wolstenholm A, Duparc S.

Antimicrob Agents Chemother · research-article; randomized controlled trial; journal article · DOI 10.1128/aac.01588-16

Bibliografisk träff 2016-11-11

Stimulation of Suicidal Erythrocyte Death by Tafenoquine.

Al Mamun Bhuyan A, Bissinger R, Stockinger K, Lang F.

Cell Physiol Biochem · journal article · DOI 10.1159/000452514

Bibliografisk träff 2016-07-26

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Ebstie YA, Abay SM, Tadesse WT, Ejigu DA.

Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s61443

Bibliografisk träff 2016-05-01

PFMDR1 POLYMORPHISMS INFLUENCE ON IN VITRO SENSITIVITY OF THAI PLASMODIUM FALCIPARUM ISOLATES TO PRIMAQUINE, SITAMAQUINE AND TAFENOQUINE.

Kaewpruk N, Tan-ariya P, Ward SA, Sitthichot N, Suwandittakul N, Mungthin M.

Southeast Asian J Trop Med Public Health · research support, non-u.s. gov't; journal article

Bibliografisk träff 2016-02-18

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.

St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, Beaumont C, Llanos-Cuentas A, Rueangweerayut R, Krudsood S, Green JA, Rubio JP.

Malar J · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/s12936-016-1145-5

Bibliografisk träff 2015-11-26

Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.

Dow GS, Liu J, Lin G, Hetzell B, Thieling S, McCarthy WF, Tang D, Smith B.

Malar J · comparative study; research-article; randomized controlled trial; journal article · DOI 10.1186/s12936-015-0991-x

Bibliografisk träff 2015-10-23

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

Beck HP, Wampfler R, Carter N, Koh G, Osorio L, Rueangweerayut R, Krudsood S, Lacerda MV, Llanos-Cuentas A, Duparc S, Rubio JP, Green JA.

J Infect Dis · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/infdis/jiv508

Bibliografisk träff 2015-07-20

The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei.

Carvalho L, Martínez-García M, Pérez-Victoria I, Manzano JI, Yardley V, Gamarro F, Pérez-Victoria JM.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00879-15

Bibliografisk träff 2015-07-01

Unexpected pharmacological and toxicological effects of tafenoquine.

Nevin RL.

Occup Med (Lond) · letter; comment · DOI 10.1093/occmed/kqv049

Bibliografisk träff 2015-04-29

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Rajapakse S, Rodrigo C, Fernando SD.

Cochrane Database Syst Rev · meta-analysis; research support, non-u.s. gov't; systematic review; systematic-review; journal article · DOI 10.1002/14651858.cd010458.pub2

Bibliografisk träff 2015-04-18

Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Campo B, Vandal O, Wesche DL, Burrows JN.

Pathog Glob Health · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1179/2047773215y.0000000013

Bibliografisk träff 2015-04-13

Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.

Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, Nolan CK, Sciotti RJ, Zottig VE, Nanayakkara NP, Tekwani BL, Walker LA, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Smith B, Marcsisin SR.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00343-15

Bibliografisk träff 2015-02-05

Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.

Cannon J, Fitzgerald B, Seed M, Agius R, Jiwany A, Cullinan P.

Occup Med (Lond) · journal article · DOI 10.1093/occmed/kqu193

Bibliografisk träff 2013-12-01

Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, Duparc S, Möhrle JJ, Webster A, Stinnett S, Hughes A, Griffith S, Beelen AP.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/bcp.12160